- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Brenna Moreno (Bren)
Insights 7 results
Client Alert
December 19, 2023
The Administration Takes Aim At Drug Prices Again – This Time Through A Controversial Framework for Exercising March-In Rights
Client Alert
August 24, 2023
FDA Issues Draft Guidance for Obtaining Postmarket Data on Underrepresented Populations in Drug Clinical Trials
Client Alert
March 27, 2023
With Risk Comes Responsibility: EU Proposes High-Risk AI Regulation Affecting Device Manufacturers
Client Alert
March 7, 2023
FDA Issues Draft Guidance on “External Controls” in Clinical Trials to Support Safety and Efficacy of a Drug
Client Alert
January 23, 2023
2022 Year in Review: FDA Drug and Device Advertising and Promotion Enforcement
Client Alert
December 19, 2022
FDA Warns Drug & Device Firms Against Delaying & Limiting Facility Inspections in New Draft Guidance